Runge et al. [39] investigated the repair proficiency in lymphocytes of prostate cancer patients over six therapy cycles with [223Ra]RaCl2 by quantifying γ-H2AX foci before each cycle, but did not analyze the induction of the DSBs during the therapy. The gene discussed is H2AX; the disease is prostate carcinoma.